Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2017 Jul 12



Publication history
Cite this article as


A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984



Minerva Urologica e Nefrologica 2017 Jul 12

DOI: 10.23736/S0393-2249.17.02976-9


language: English

Castration resistance prostate cancer: what is in the pipeline?

Cosimo DE NUNZIO 1 , Fabrizio PRESICCE 1, Silvana GIACINTI 2, Maria BASSANELLI 2, 3, Andrea TUBARO 1

1 Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy; 2 Department of Oncology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy; 3 Department of Oncology, Ospedale San Camillo De Lellis, Rieti, Italy


INTRODUCTION: To evaluate the available evidence on the standard diagnosis and management of men with metastatic castration resistant prostate cancer (mCRPC), and providing the timely update on new pharmacological treatments.
EVIDENCE ACQUISITION: A systematic literature search from from January 2000 until March 2017 was performed by combining the following MESH terms: castrate resistant prostate cancer, abiraterone, enzalutamide, 223radium, sipuleucel-T, docetaxel, cabazitaxel, resistance mechanisms, resistance to androgen deprivation, Androgen Receptor (AR) mutations, amplifications, splice variants, and AR alterations. We followed the Preferred Reporting Items for
Systematic Review and Meta-Analysis (PRISMA).
EVIDENCE SYNTHESIS: In the few last years the introduction of new treatment modalities as abiraterone or enzalutamide have significantly change our prospective in mCRPC management increasing patients survival and quality of life. The standard imaging modalities to define the presence of regional or distant metastasis or the different resistant mechanisms to the available treatments are still an issue of debate, however several studies are ongoing to define the standard of care and to reduce treatments’ resistance. Data from ongoing phase III trials are awaited to introduce in clinical new effective
treatments that can be used in patients resistant to abiraterone/enzalutamide or more probably in a different phase of the disease.
CONCLUSION: Castration resistant prostate cancer is now the key issue in prostate cancer management and
research. Our challenge in the near future will be to identify the right treatment or better the right combination and sequencing of treatments that should be used in patients with mCRPC or even with advanced prostate cancer.

KEY WORDS: Prostate cancer - Castration resistant - Oncology - Diagnosis - Pharmacological treatment

top of page

Publication History

Article first published online: July 12, 2017
Manuscript accepted: June 28, 2017
Manuscript received: May 23, 2017

Cite this article as

De Nunzio C, Presicce F, Giacinti S, Bassanelli M, Tubaro A. Castration resistance prostate cancer: what is in the pipeline?. Minerva Urol Nefrol 2017 Jul 12. DOI: 10.23736/S0393-2249.17.02976-9

Corresponding author e-mail